It is worth noting that the three glucose meters that showed an interference measure glucose by electrochemical methods. The reflectance methodology used in the other two glucose meters did not show such an interference. The kit inserts provided by the manufacturers of Elite and Accu-chek Advantage do not state that such interference exists. The Precision QID information package does discuss a possible negative bias. The issue of interferences from reductive compounds such as acetaminophen on electrochemical glucose sensors has been addressed before (2). Despite a 1992 report (3) on the Glucocard glucose meter (another brand name for the Bayer Elite), which identified a positive bias with acetaminophen, this issue has not been addressed in the recently published reports dealing with electrochemical glucose meters (4 -10). Kit inserts should carry this information. The magnitude of the positive bias seen here with the Glucometer Elite and Accu-chek Advantage is such that the clinical management of patients suffering from acetaminophen intoxication and its complications (one being hypoglycemia) might be affected negatively.
Why "Urea Nitrogen" When Urea is Measured?
To the Editor: The paper by Morishita et al. (1) regarding the analysis of urea is confusing. In the text, the authors state that they are measuring urea nitrogen (UN), and it may seem so, because their calibrators were "physiological saline, with and without 17.86 mmol/L UN". However, the abstract states that analytical recovery of added urea was studied with patient sera containing 6.14 mmol/L urea. In contrast, the text describes patient sera with a UN concentration of 6.14 mmol/L. Because urea contains two nitrogens, these two sentences seem to be incompatible.
I think that if one is measuring urea, one should give the results in SI units (mmol/L) for the whole compound and not for the urea nitrogen. Otherwise, ambiguities arise in the interpretation of the results. Urea should be measured, and "urea nitrogen" should be abandoned as an analyte in clinical chemistry work. 
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Editor's note: An author in Reference 1, aware that urea nitrogen contains two N, indicates that "N 2 (nitrogen molecule)" was used for the calculation. He apologizes for the confusion.
Total and Non-Protein-bound Fractions of 3,4-Dihydroxyphenylalanine
To the Editor: Several analytical methods for the determination of plasma 3,4-dihydroxyphenylalanine (l-DOPA) by HPLC have been reported. Many of these methods require preliminary purification of the plasma sample. Such purification procedures include adsorption on alumina (1) and solidphase (2) or solvent extraction (3) . The direct injection of deproteinized plasma supernatant (4) and the determination of the non-proteinbound fraction by ultrafiltration (5) offer simplified alternatives for rapid assay.
Dethy et al. (6) , propose microdialysis-HPLC to determine l-DOPA and its metabolites (3,4-dihydroxyphenylacetic acid, dopamine, and homovanillic acid) in the plasma of patients with advanced Parkinson's disease. We would like to make a number of comments concerning this attractive new method. First, it should be noted that microdialysis excludes large molecules (the authors do not specify the molecular weight excluded by the membrane) and thus separates protein-bound l-DOPA that is not dialyzed from unbound l-DOPA that passes through the membrane. Although l-DOPA binds to plasma proteins only to a minor extent, the unbound fraction is influenced by the total concentration in the sample. In fact, it increases from an average of ϳ70% at 100 g/L l-DOPA to ϳ90% at 1000 g/L (7) . Although for therapeutic drug monitoring purposes unbound plasma concentrations are considered to more accurately reflect drug concentrations at the site of action, variability in protein binding implies that results in plasma dialysates and whole plasma may not be comparable.
Another important issue is the poor stability of l-DOPA, particularly when it is separated from its plasma matrix. Addition of antioxidants like ascorbic acid (5 mM) or sodium metabisulfite (5 mM) does not markedly improve the stability of an aqueous solution of l-DOPA, whose concentration, even in the presence of the above antioxidants, decreases by 60% after 3 hours at room temperature (8) . Moreover, antioxidants may increase the background current of the electrochemical detector and may give rise to additional unidentified peaks (8) . It would, therefore, be important to determine the stability of the drug in plasma and dialysates using the antioxidant solution proposed by the authors.
Finally, with respect to the chromatographic separation, the peaks of l-DOPA, 3,4-dihydroxyphenylacetic acid, and DA are not well separated from each other, from the solvent front, or from two unidentified peaks. For these reasons, it would be useful to know the procedures used to confirm the identity of peaks and to exclude possible coelution with unidentified substances.
